Search Results
Aug 21, 2025, 08:00 ET STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ELAMIPRETIDE NDA RESUBMISSION
August 15, 2025, following its receipt of a May 2025 complete response (CR). As recommended by the FDA in the CR, the resubmission seeks accelerated approval of elamipretide on the basis of improvements in knee extensor muscle strength, an intermediate
More news about: Stealth BioTherapeutics Inc.
Aug 20, 2025, 11:58 ET Global Times: Development opportunities, potential and advantages should be better used
development. At sea, the country's second domestically built large cruise ship, the Adora Flora City, successfully completed its float-out. On land, the CR450 electrical multiple unit, the world's fastest high-speed train with a test speed of 450 kilometers per hour, has redefined new global benchmarks for
More news about: Global Times
Aug 19, 2025, 12:21 ET IAN Group appoints Chintan Thakkar as Group CEO and Senior Managing Partner, IAN Alpha Fund
and Sarika Saxena, is significantly strengthened, giving us the management bandwidth to achieve our vision of Rs. 5000 Cr investment, spawning 500 startups and creating 500,000 jobs'. IAN brought the concept of angel investing to India,
More news about: IAN Group
Aug 19, 2025, 06:39 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
CohortORR: 40% (10/25), including 1 CRDCR: 84% (21/25)CLDN18.2 Low and Ultra-low expression (IHC 2+ ≤ 20%)Efficacious dose range of 1.8-2.4 mg/kgORR: 33.3% (6/18), including 1 CRDCR: 50% (9/18)Notably, some
More news about: Antengene Corporation Limited
Aug 19, 2025, 00:42 ET Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
CohortORR: 40% (10/25), including 1 CRDCR: 84% (21/25)CLDN18.2 Low and Ultra-low expression (IHC 2+ ≤ 20%)Efficacious dose range of 1.8-2.4 mg/kgORR: 33.3% (6/18), including 1 CRDCR: 50% (9/18)Notably, some
More news about: Antengene Corporation Limited
Aug 18, 2025, 08:00 ET STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
manufacturing observations cited in the CR have been resolved, and the progress we have made to align on post-marketing trial design, we believe that all concerns raised by the FDA have been addressed." In May 2025, the FDA issued a CR recommending resubmission of Stealth's
More news about: Stealth BioTherapeutics Inc.
Aug 15, 2025, 07:00 ET EAF lança a caravana do programa Brasil Antenado em São Miguel do Gostoso
https://mma.prnewswire.com/media/2751147/Brasil_Antenado__Cr_dito__Divulga__o_EAF.jpg
More news about: Entidade Administradora da Faixa (EAF)
Aug 14, 2025, 16:05 ET Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
with dabogratinib at 50 mg once-daily (QD) (Cohort 1) or treatment with dabogratinib at 60 mg QD (Cohort 2). The primary endpoint is complete response (CR) rate at three months. Secondary endpoints include time to recurrence, median duration of response, recurrence free survival, progression free survival,
More news about: Tyra Biosciences
Aug 14, 2025, 09:00 ET DuPont Water Solutions Wins BIG Sustainability Award for Advancements in Industrial Wastewater Reuse
Over the past year, DuPont has introduced several new and upgraded FilmTec™ Fortilife™ membranes to the market — including product grades such as CR100, XC70, XC120HR, and XC160 — pushing the boundaries of brine concentration and energy efficiency. These innovations not only support global momentum
More news about: DuPont
Aug 14, 2025, 05:25 ET UGRO CAPITAL ANNOUNCES FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025
INR 12,081 Cr, up 31% YoYTotal Income stood at INR 421.8 Cr in Q1'FY26, up 40% YoYNet Total Income at INR 216.5 Cr, up 31% YoYGNPA/NNPA at 2.5%/1.7% on total AUMEmbedded Finance Growth: Reached INR 1,011 Cr AUM with INR 582 Cr disbursed in
More news about: UGRO Capital Limited
Aug 14, 2025, 00:55 ET Q1 FY26 - Delivers 63% YoY PAT Growth; Strengthens Balance Sheet with ₹900 Cr QIP
multimedia:https://www.prnewswire.com/in/news-releases/q1-fy26---delivers-63-yoy-pat-growth-strengthens-balance-sheet-with-900-cr-qip-302529809.html
More news about: Marathon NextGen Realty Ltd
Aug 12, 2025, 16:05 ET INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
initial 12-month Phase 1/2 trial (Year 1) to 86% at the end of the second 12-month period (Year 2)Patients experiencing a Complete Response (CR - 0 surgeries per year) increased from 28% for Year 1 to 50% for Year 2Mean number of surgeries was reduced from 4.1 in the pre-treatment period
More news about: INOVIO Pharmaceuticals, Inc.
Aug 12, 2025, 09:00 ET VELOCITY STABILIZES RESTOMOD INDUSTRY WITH THE ACQUISITION OF CLASSIC RECREATIONS
industry, the world's largest bespoke restomod company acquires the assets of Classic Recreations, expanding its product offerings and supporting existing CR customers. PENSACOLA, Fla., Aug.
More news about: Velocity Modern Classics
Aug 12, 2025, 09:00 ET Mercury Insurance Unveils This Year's Most Affordable New Trucks and SUVs to Insure
FeHonda PilotChevrolet BlazerKia SportageHonda PassportFord EscapeKia SoulHonda HR-VHonda CR-VKia Sorento"Choosing a vehicle with utility doesn't have to break the bank, as any of these vehicles
More news about: Mercury General Corporation
Aug 12, 2025, 07:30 ET ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL
More news about: ADC Therapeutics SA
Aug 12, 2025, 05:50 ET Steele Honda Adds the 2026 Honda CR-V to Its Inventory in St. John's, Newfoundland
Aug. 12, 2025 /PRNewswire/ -- Drivers in St. John's can now test drive the 2026 Honda CR-V at the Steele Honda dealership.
More news about: Steele Honda
Aug 12, 2025, 04:19 ET Caliway Met Dual Milestones with MSCI Global Standard Index Inclusion, and Health Canada has Approved the Phase 3 SUPREME-01 Study
accordance with U.S. FDA guidance and relevant regulations, including the FDA's guideline on Patient-Focused Drug Development. The Clinician Reported-AFRS (CR-AFRS) and the Patient Reported-AFRS (PR-AFRS) are used to assess treatment response based on the physician's evaluation and the participant's self-assessment,
More news about: Caliway Biopharmaceuticals
Aug 11, 2025, 08:05 ET Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1Mean number of surgeries patients needed to control their RRP continued to drop from
More news about: INOVIO Pharmaceuticals, Inc.
Aug 07, 2025, 09:03 ET Crunch Fitness Franchisee CR Fitness Holdings Donates Gym Equipment to New Ronald McDonald House at St. Joseph's Children's Hospital
RMHCTB helps families focus on what matters most, caring for their child. For more information, visit rmhctampabay.org. About CR Fitness Holdings, LLCCR Fitness Holdings, LLC is the leading franchisee of Crunch Fitness. Led by industry veterans Vince Julien,
More news about: CR Fitness Holdings, LLC.
Aug 07, 2025, 01:25 ET A23 launches the 3rd season of Rummy Indian Open with a ₹25 Crore prize pool and a high-stakes finale in Goa
starts August 1, 2025 and will conclude on September 30, 2025. With a prize pool of over ₹25 Cr, RIO is set to unite over 3.5 lakh rummy enthusiasts, competing with each other on the A23 Rummy app.
More news about: Head Digital Works
Aug 06, 2025, 14:30 ET NIIT Learning Systems Limited (NIIT MTS) Announces Q1 FY'26 (April-June 2025) Results
June 2025 quarter, the company recorded a consolidated Net Revenue of Rs. 451.4 Cr, up 5% QoQ and 11% YoY. EBITDA was Rs. 95.1 Cr while EBITDA Margin stood at 21%. Profit After Tax was Rs. 49.3 Cr. EPS for the quarter was Rs. 3.62. The results were taken on record at the meeting of
More news about: NIIT (USA), INC.
Aug 05, 2025, 08:39 ET Tarrytown Honda Earns Honda President's Award
with the HR-V, CR-V, Passport, Prologue and Pilot sport utility vehicles, the Ridgeline pickup and the Odyssey minivan. The Honda electrified vehicle lineup, representing more than a quarter of total sales in 2024, includes the all-electric Prologue SUV, hybrid-electric Accord, CR-V, and Civic, and Fuel-Cell-electric
More news about: Tarrytown Honda
Jul 31, 2025, 16:01 ET Coveo Reports First Quarter Fiscal 2026 Financial Results
https://emportal.ink/44cR5CQUse the link above to join the conference call without operator assistance. If you prefer to have operator assistance, please
More news about: Coveo Solutions Inc.
Jul 31, 2025, 11:31 ET Aarti Industries Demonstrates Resilience in Challenging Q1; Strategic Expansions and Diversified Portfolio Set Stage for Recovery
long-term growth agenda. On a consolidated basis, income from operations stood at ₹ 1,867 Cr, compared to ₹ 2,214 Cr in Q4 FY25. EBITDA stood at ₹ 215 Cr, while Profit After Tax (PAT) stood at ₹ 43 Cr. While financial performance was impacted in the short term, the underlying health of the business
More news about: Aarti Industries
Jul 31, 2025, 08:30 ET Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition,
More news about: Actinium Pharmaceuticals, Inc.